Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged older than 14 up to and including 65 years old
- People who have been diagnosed with a specific type of blood cancer called ETP-ALL, Near-ETP-ALL, or T-ALL with certain genetic changes — confirmed through specialised laboratory tests of blood or bone marrow cells
- People who have not yet received main treatment (induction therapy) for this diagnosis before enrolling — though some limited prior medications such as hydroxyurea, dexamethasone, low-dose cytarabine, a small amount of venetoclax, or a blood-filtering procedure are acceptable
- People who are reasonably active and able to carry out daily activities, as measured by a standard medical scoring tool (a score of 0–2 on the ECOG scale)
- People whose doctors expect them to survive for more than 6 months
- People who are able to understand the study information and agree to take part by signing a consent form
Who may not be able to join:
- People who are pregnant, breastfeeding, or who are of childbearing potential and are unwilling to use contraception during the trial
- People who have an active infection that is not under control, including bacterial, fungal, or viral infections, or who currently have active Hepatitis B, Hepatitis C, or HIV
- People with serious heart problems, such as poor heart pumping function, a history of heart failure, unstable heart disease, or a severe irregular heartbeat
- People with serious breathing problems, as shown by low oxygen levels in the blood
- People with significant liver problems, shown by certain blood test results being well above the normal range
- People with significant kidney problems, shown by certain blood test results or kidney function measurements being outside acceptable ranges
- People who have had a serious allergic reaction to any of the medicines used in this trial or to closely related medicines
- People whose leukaemia has spread to the central nervous system (the brain and spinal cord)
- People whom the trial doctor considers unsuitable for participation for any other reason (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86+051267781850
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite Complete Remission Rate（CRc） after induction therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.